128 related articles for article (PubMed ID: 17726011)
21. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
22. Kinetically coupled folding of a single HIV-1 glycoprotein 41 complex in viral membrane fusion and inhibition.
Jiao J; Rebane AA; Ma L; Gao Y; Zhang Y
Proc Natl Acad Sci U S A; 2015 Jun; 112(22):E2855-64. PubMed ID: 26038562
[TBL] [Abstract][Full Text] [Related]
23. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
24. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
25. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
26. Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV-1.
Ikeda T; Tennyson RL; Walker SN; Harris RS; McNaughton BR
ACS Infect Dis; 2019 Apr; 5(4):634-640. PubMed ID: 30811933
[TBL] [Abstract][Full Text] [Related]
27. Blocking HIV entry.
Buzko OV; Shokat KM
Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
[TBL] [Abstract][Full Text] [Related]
28. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
Kliger Y; Shai Y
J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
[TBL] [Abstract][Full Text] [Related]
30. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
31. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.
Bewley CA; Louis JM; Ghirlando R; Clore GM
J Biol Chem; 2002 Apr; 277(16):14238-45. PubMed ID: 11859089
[TBL] [Abstract][Full Text] [Related]
32. The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions.
Koshiba T; Chan DC
J Biol Chem; 2003 Feb; 278(9):7573-9. PubMed ID: 12486032
[TBL] [Abstract][Full Text] [Related]
33. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
34. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody.
Jiang S; Lin K; Zhang L; Debnath AK
J Virol Methods; 1999 Jun; 80(1):85-96. PubMed ID: 10403680
[TBL] [Abstract][Full Text] [Related]
35. The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.
Louis JM; Baber JL; Clore GM
Biochemistry; 2015 Nov; 54(45):6796-805. PubMed ID: 26506247
[TBL] [Abstract][Full Text] [Related]
36. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
Jin BS; Lee WK; Ahn K; Lee MK; Yu YG
J Biomol Screen; 2005 Feb; 10(1):13-9. PubMed ID: 15695339
[TBL] [Abstract][Full Text] [Related]
37. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.
Golding H; Zaitseva M; de Rosny E; King LR; Manischewitz J; Sidorov I; Gorny MK; Zolla-Pazner S; Dimitrov DS; Weiss CD
J Virol; 2002 Jul; 76(13):6780-90. PubMed ID: 12050391
[TBL] [Abstract][Full Text] [Related]
38. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
39. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.
Liu S; Wu S; Jiang S
Curr Pharm Des; 2007; 13(2):143-62. PubMed ID: 17269924
[TBL] [Abstract][Full Text] [Related]
40. Design and Biological Evaluation of
Meng G; Pu J; Li Y; Han A; Tian Y; Xu W; Zhang T; Li X; Lu L; Wang C; Jiang S; Liu K
J Med Chem; 2019 Oct; 62(19):8773-8783. PubMed ID: 31513410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]